

## VACCINE CONGRESS

Celebrating 25 years of Publication

9 - 11 December 2007 | Amsterdam, The Netherlands

<b>Sunday December 9, 2007</b>		
13:30	Ray Spier University of Surrey, UK and Editor of Vaccine	Welcome
<b>Session1</b> <b>Social issues with vaccines and vaccination</b> <b>Part one: current issues and areas for development</b>		
13:37	P.L. Nara Biological Mimetics Inc, USA	Perspectives on advancing the field of vaccinology at the wild, domestic, laboratory, veterinary and human interface: not missing the opportunities
14:07	L. Hessel Sanofi Pasteur MSD, France	25 years of vaccine development: an industry perspective
14:22	M.P. Girard Viovision Lyon, France	HIV/AIDS vaccines: An update
14:37	J. Shiver Merck Research Laboratories, USA	Strategies for HIV-1 vaccine development
14:52	C. Myint Oo Chiba Institute of Technology, Japan	HIV-GagVLPs induce activation of innate and adapted immune responses by activation of dendritic cells, T cells and NK cells
15:07	S.T. Turbant CEA, DSV, iBiTec-S, SPI, LIAS, France	Evaluation of the immunogenicity of a new Tat candidate vaccine against HIV, in a non human primate model
15:14	F. Martinon CEA, France	Induction of persistent T Cell responses against HIV in macaques with a multivalent DNA vaccine injected intradermally with electroporation
15:21	K. Alagappan Long Island Jewish Medical Center, USA	Protective titers and immunizable diseases among HIV infected patients
15:28	D. Weiner University of Pennsylvania, USA	Enhanced DNA vaccine potency and immune phenotype targeting HIV-1
16:00	<i>Refreshments, poster session 1 and exhibition viewing</i>	
<b>Session 2</b> <b>Latest status in the development of vaccines for TB, malaria and HIV</b>		
16:28	X. Bosch Institut Catala d'oncologia, Spain	HPV vaccines for cancer prevention
16:43	J.C. Sadoff Aeras Global TB Vaccine Foundation, USA	Development of new vaccines to address the TB pandemic
16:58	M. Romano Pasteur Institute Brussel-WIV, Belgium	Immunogenicity and protective efficacy of ppe44-based tuberculosis subunit vaccines

17:05	F. Dobakhti Zanjan University of Medical Sciences, Iran	Oral administration of BCG encapsulated in alginate microspheres induces protective immunity in BALB/c mice
17:12	A. Dey All India Institute of Medical Sciences, India	Developing a chimeric DNA vaccine against tuberculosis and leishmaniasis
17:19	G.H. Mitchell Guy's Kings College and St. Thomas' Hospitals' School of Medicine, UK	Resisting malaria
17:33	A.Reyes-Sandoval University of Oxford, UK	Immunogenicity and protective efficacy of simian adenoviral vectors against <i>P. berghei</i>
17:40	K. Pusic University of Hawaii, USA	Antigenicity and immunogenicity of the <i>P. falciparum</i> merozoite surface protein, MSP1-33
17:47	A.Mohd Nor University Science Malaysia, Malaysia	Immunogenicity and in vitro protective efficacy of recombinant <i>Mycobacterium bovis</i> bacilli Calmette Guerin (BCG expressing the 19kDa C-terminus of merozoite surface protein-1 (MSP-1C) and the 22 kDa of serine repeat antigen (SE22) of <i>Plasmodium falciparum</i>
17:54	V. Chitnis Pharmexa-Epimmune, USA	Pre-clinical development of a pre-erythrocytic <i>P. falciparum</i> malaria DNA vaccine based on conserved cytotoxic T Lymphocyte and Helper T Lymphocyte Epitopes delivered by an in vivo electroporation device
18:01	M. Roestenberg Radboud University Nijmegen Medical Centre, Netherlands	Comparison of safety and immunogenicity of AMA-1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 and AS02A
18:08	Discussion	
18:15	G.A. Poland Mayo Clinic College of Medicine, USA	Variations in vaccine response: The role of immunogenetics: Bench to bedside to population
Reception and poster session 1		

### Monday December 10, 2007

#### Session 3

**New and upcoming issues with other vaccines including : Influenza H5N1 vaccines, HPV Vaccines, biowarfare vaccines, respiratory vaccines, diarrhoeal vaccines**

8:30	A.D.M.E. Osterhaus Erasmus MC, Netherlands	Vaccination against emerging viral infections
8:55	A.M. Palache Solvay Pharmaceuticals BV, Netherlands	Seasonal influenza control: Urgent time for actions
9:20	U. Reichl Max Planck Institute for Dynamics of complex Technical Systems, Germany	Influenza vaccines – challenges in optimization of virus yields in mammalian cell culture
9:45	M. Rudolf Friedrich-Loeffler-Institut, Federal	Long-term study under field conditions on the efficacy of commercial, inactivated H5 influenza vaccines against

	Research Institute for Animal Health, Germany	highly pathogenic avian influenza H5 in poultry
9:52	S. Mossman GlaxoSmithKline Biologicals, Belgium	Immunization of ferrets with low doses of influenza H5N1 antigen formulated with a novel adjuvant system protects against lethal challenge with Heterologous H5N1 Virus
9:59	I.Leroux-Roels Ghent University and Hospital, Belgium	Pandemic influenza preparation: Cross-reactive immunity with an adjuvanted H5N1 candidate vaccine associated with a good safety profile
10:06	C. He Agricultural University, China	Whole virion H5N1 inactivated vaccine against highly pathogenic avian influenza
10:13	D. Higgins Dynavax Technologies, USA	Immunostimulatory DNA conjugated to conserved viral antigens as a universal influenza vaccine
10:28	P. Bilsel Pharmexa-Epimmune, USA	T-Lymphocyte epitope based vaccine for pandemic influenza
10:35	T.V. Nguyen Company for Vaccine and Biological Production No. 1 (VABIOTECH), Vietnam	Development of a human H5N1 influenza vaccine by reverse genetics in Vietnam
10:42	Discussion	Cross protective influenza vaccines - prospects
10:55	<i>Refreshments, poster session 1 and exhibition viewing</i>	
<b>Session 4</b>		
<b>Methods of vaccine production focusing on the new areas of plasmid vaccines, whole cell vaccines and others</b>		
11:20	R. Strugnell University of Melbourne, Australia	Whither Salmonella vaccine, vectors
11:45	C.B. Palatnik de Sousa Federal University of Rio de Janeiro, Brazil	Vaccines for Leishmaniasis in the forecoming 25 years
12:00	A.Zanetti University of Milan, Italy	Vaccination against Hepatitis B: A historical overview
12:15	A.Bianchi University at Buffalo, USA	The role of the CYS-PAM3 motif of Nontypeable Haemophilus Influenzae OMP P6 in stimulating innate immune responses
12:30	K.Roland AVANT Immunotherapeutics, Inc., USA	Construction and preclinical evaluation of a V. cholerae Peru-15 (CholeraGarde®) strain that expresses high levels of CTB for use as a vaccine against enterotoxigenic Escherichia coli
12:45	F. Roohvand Pasteur Institute of Iran, Iran	Construction and evaluation of CD8-polytope DNA constructs based on immunodominant and sub-dominant HCV epitopes
13:00	M. Doskaya Ege University Medical School, Turkey	Immunogenic anti-Osporozoite vaccine candidate against Toxoplasmosis
13:10	<i>Lunch, poster session 1 and exhibition viewing</i>	

<b>Session 5</b> <b>Immunological aspects of vaccines; Adjuvanting vaccines – methods, targets, mechanisms, materials and presentation</b>		
14:15	I.G. Ovsyannikova Mayo Clinic College of Medicine, USA	Influence of host genetic variation on the immune response to the smallpox vaccine
14:22	J. Kyd Central Queensland University, Australia	Targeting mucosal vaccine delivery and differential immune modulation against respiratory bacterial infection
14:37	V.E.J.C. Schijns Intervet Int. BV, Netherlands	The importance and mechanistic activities of vaccine adjuvants
14:52	W.A. Jeffries University of British Columbia, Canada	TAP as a general adjuvant to augment immune responses to low-dose vaccination
15:07	K.S.Korsholm Statens Serum Institut, Denmark	The new versatile DDA-TDB adjuvant system enhances the protective efficacy of vaccines against both malaria and tuberculosis
15:22	B.D. Livingston Dynavax Technologies, USA	Development of immunostimulatory Oligonucleotides as vaccine adjuvants
15:29	Ch. Hartoonian Tehran University of Medical Sciences, Iran	Administration of GM-CSF (Granulocyte-Monocyte Colony Stimulating Factor) and IL-23 enhances immune responses generated against Hepatitis C virus core DNA prime-protein boost immunization
15:36	X.M. Song Zhejiang University, China	Adjuvant activity of Ginseng nanoparticles (Ginsomes) on the immune responses to Ovalbumin in BABG/c mice
15:45	<i>Refreshments, poster session 2 and exhibition viewing</i>	
<b>Session 6</b> <b>Correlates of protection; clinical trials; regulatory agencies</b>		
16:15	S.A. Plotkin University of Pennsylvania, USA, Sanofi Pasteur, USA	Correlates of vaccine induced immunity
16:45	K. Gijzen Netherlands Vaccine Institute (NVI), Netherlands	Identification of new correlates of protection against influenza
17:00	J.A.C. Schalk Centre for biological Medicines and Medical Technology, Netherlands	Infectivity PCR, a rapid method for detection and quantification of infectious viruses in live virus vaccines and gene therapeutics
17:15	K.A.Bryant University of Louisville, USA	Safety and immunogenicity of a 13-valent Pneumococcal conjugate vaccine in infants
17:30	C. Martin University of Zaragoza, Spain	Attenuated live vaccines against tuberculosis based in phoP inactivation: Further studies on safety, one step to clinical trials
17:45	A.Vila-Corcoles Institut Catala de la Salut, Spain	Clinical effectiveness of pneumococcal vaccination in order adults with chronic respiratory disease
18:00	Discussion	
19:00	<b>Congress dinner with after-dinner speech, “Vaccine”: The journal and the future; R.E. Spier, University of Surrey, UK and Editor of Vaccine</b>	

Tuesday December 11, 2007

**Session 7**

**Vaccines to non-infectious diseases; Cancer vaccines; Therapeutic vaccinations; Social vaccines; Vaccines to addiction**

8:30	R.G. van der Most National Research Centre for Asbestos Related Diseases, Australia	Turning the tumor into its own vaccine: Adding context to content
8:45	E. Barr Merck Research Laboratories, USA	Primary prevention of cervical cancer and beyond – GARDASIL (Quadrivalent Human Papillomavirus {HPV} Vaccine)
9:00	T.G. Wu University of Minnesota, USA	A potential roadmap for the development of cancer vaccines
9:15	L. Krishnan National Research Council-Institute for Biological Sciences, Canada	Archaeosome adjuvants for tumor immunotherapy: Modulation of potent CD8+ T Cell memory of the central and effector phenotype, comparison to live bacterial vaccine vectors
9:22	H. Hossein Velindre NHS Trust, UK	Evaluation of clinical-grade poly I:C-analogue (Ampligen®) as a potential adjuvant for human dendritic cell (DC) maturation for cell mediated cancer immunotherapy
9:29	J. Jasinska Medical University of Vienna, Austria	Virosome-based multi-epitope vaccine against Her-2/neu overexpressing tumors: from bench to clinic
9:35	R.W. Hepler Merck Research Laboratories, USA	Development of multi antigenic peptide antigens as the basis for a novel vaccine approach to Alzheimer's disease
9:50	A. Neisig Pharmexa A/S, Denmark	Development of a PADRE-RANKL vaccine against osteoporosis
10:05	B. Anton National Institute of Psychiatry, Mexico	Preclinical studies on generation of highly immunogenic conjugates for psychotropic substances
10:20	J.A. Duckworth National Research Centre for Possum Biocontrol at Landcare Research, New Zealand	Fertility control vaccines for wildlife management in New Zealand
10:35	Discussion	
10:45	<i>Refreshments, poster session 2 and exhibition viewing</i>	

**Session 8**

**Modern vaccine designs; T-Cells, genomics, immunogenetics; Conjugates; Cross-fertilization between human and veterinary areas**

11:15	P.L. Nara Biological Mimetics, Inc., USA	Circumventing deceptive imprinting: A maginot line to making broadly protective vaccines?
11:45	R. Rappuoli Novartis Vaccines, Italy	Vaccines in the era of genomics and toll-like receptors
12:15	.Jordan ProBioGen AG, Germany	The duck Cell Line AGE1cr for the production of vaccine vectors

12:27	S.C. Wu National Tsing Hua University, Taiwan	High genetic stability of dengue virus propagation in MRC-5 cells and the comparison of viral yields to Vero cells on microcarriers
12:39	Discussion	
12:45	<i>Lunch, poster session 2 and exhibition viewing</i>	

### Session 9

#### Vaccine formulation, preservations, storage, delivery; Attitudes to vaccination

13:45	B. Weniger U.S. Centers for Disease Control and Prevention (CDC), USA	Alternative and future vaccine delivery technologies and preparedness for mass campaigns
14:15	H. Kiyona University of Tokyo and CREST, Japan	The mucosal immune system for the development of needle-a and cold chain-free vaccine
14:30	P-P. Pastoret World Organisation for Animal Health ,France	The story of fox vaccination against rabies using a recombinant Vaccinia-rabies virus
14:45	D.R.M. Negri Istituto Superiore di Sanita, Italy	Successful immunization with a single injection of nonintegrating lentiviral vector
15:00	R. Greco University of Milan, Italy	Production of recombinant HIV-1/HBV virus-like particles in Nicotiana tabacum and Arabidopsis thaliana plants for a bivalent plant-based vaccine
15:15	A.Luxembourg Ichor, USA	Electroporation based delivery improvise immunogenicity and potency of DNA vaccines
15:30	J.F. McGrath Central Queensland University, Australia	Evaluation of bacterial ghost mucosal delivery technology on immunogenicity of nontypeable Haemophilus influenzae mono- and multi-valent antigens
15:37	J.H.B.H. Hirschberg Netherlands Vaccine Institute, Netherlands	Bioneedles <sup>TM</sup> : A parenteral vaccine technology platform avoiding classical syringe and needle
15:44	B.H.A. Kremer OctoPlus NV, Netherlands	Single-shot vaccines: controlled delivery by OctoVAX- <sup>TM</sup> microspheres
15:51	Discussion	
16:00	<i>Refreshments, poster session 2 and exhibition viewing</i>	

### Session 10

#### Social issues with vaccines and vaccination

#### Part two: Where are we going locally and globally and how we are going to pay for it

16:30	A.McDermott International AIDS Vaccine Initiative, USA	Fostering innovation in AIDS vaccine development
17:00	J.B. Campbell University of Toronto, Canada	Vaccination attitudes of medical, chiropractic and naturopathic students
17:30	W.L. Straus Merck & Co., Inc., USA	Ethical considerations in international vaccine research: Consensus and evolving debate

17:45	S. Hilton MRC, Social and Public Health Sciences Unite, UK	Aligning advice with the evidence: Trends in commentaries and editorials during the MMR controversy
18:00	G. Gandhi International AIDS Vaccine Initiative, USA	Demand forecasting for global health products: Recent advances and the role of Public-Private Partnerships (PDPs) (PANEL SESSION)
<b>Concluding lecture: “The end of the beginning” ... Vaccine for the next 25 years</b> , J. Oxford, St Bartholomew’s and the Royal London Hospital, Queen Mary’s School of Medicine and Dentistry and Retroscreen Virology Ltd., UK		